Intelligence · Patents
Patents expiring in 2034
Annual patent cliff calendar for 2034 — US pharmaceutical patents by expiration date.
- Patents
- 1,452
Quick answer
1,452 indexed pharmaceutical patents have expiration dates in 2034. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 8901093
Custom vectors for treating and preventing pancreatic cancer
granted -
US 8900638
Solid preparation comprising alogliptin and metformin hydrochloride
granted -
US 8900616
System and method for satellite drug delivery
granted -
US 8900862
Mesh enclosed tissue constructs
granted -
US 8900574
Mesenchymal stem cells for the treatment of CNS diseases
granted -
US 8900599
Conjugates of Plasmodium falciparum surface proteins as malaria vaccines
granted -
US 8901173
Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
granted -
US 2014357564
Von Willebrand Factor Variants Having Improved Factor VIII Binding Affinity
granted -
US 2014356438
PERIPHERALLY ADMINISTERED VISCOUS FORMULATIONS
granted -
US 8906870
MicroRNA (miRNA) for the diagnosis and treatment of heart diseases
granted -
US 8906917
Pyrimidine cyclohexyl glucocorticoid receptor modulators
granted -
US 8907053
Immunosuppression modulating compounds
granted -
US 8907089
Fused heterocyclic ring derivative and use thereof
granted -
US 8906964
Methods of administering compositions comprising docosapentaenoic acid
granted -
US 8906949
Orally disintegrating tablets of zolmitriptan and process for preparing the same
granted -
US 8906939
3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
granted -
US 8906922
Substituted triazoles useful as AXl inhibitors
granted -
US 8906901
Administration of dipeptidyl peptidase inhibitors
granted -
US 8906897
Antimicrobial agents based on hemin derivatives
granted -
US 8906863
Proteolysis-resistant capsid of chimeric hepatitis E virus as an oral delivery vector
granted -
US 8906853
[N-Me-4-hydroxyleucine]-9-cyclosporin analogues for treatment and prevention of hepatitis C infection
granted -
US 8906668
Synergistic bacterial compositions and methods of production and use thereof
granted -
US 8906411
Pre-compacted calcium-containing compositions
granted -
US 8906384
Antiviral activity of bovine type III interferon against foot-and-mouth disease virus
granted -
US 8906358
Leishmania challenge model
granted -
US 8906353
Compositions and methods for achieving sustained therapeutic drug concentrations in a subject
granted -
US 8906151
Calcium phosphate composition and process for producing the same
granted -
US 8905913
Method and composition for synchronizing time of insemination
granted -
US 8907060
Mutated Pseudomonas exotoxins with reduced antigenicity
granted -
US 8906872
Antisense antiviral compound and method for treating ssRNA viral infection
granted -
US 8906862
Multiple antigen delivery system using hepatitis E virus-like particle
granted -
US 8906413
Drug formulations having reduced abuse potential
granted -
US 8906343
PAA nanoplatforms containing fluorophores and targeted moieties covalently linked and photosensitizer post-loaded
granted -
US 8905235
Polymeric reagents comprising a terminal vinylic group and conjugates formed therefrom
granted -
CA 2853911
PROCEDE DE FABRICATION DE MELANGES GAZEUX NO/N2 DESTINES AU DOMAINE MEDICAL
granted -
US 8911752
Methods of making compositions comprising lecithin oils and NSAIDS for protecting the gastrointestinal tract and providing enhanced therapeutic activity
granted -
US 8912316
Compositions and methods for inhibiting expression of CD45 gene
granted -
US 8912142
Method of regulating proliferation and differentiation of keratinocyes
granted -
US 8912138
DNA-binding proteins and uses thereof
granted -
US 8912172
Skin external preparation containing triterpenic acid
granted -
US 8912170
Prodrugs of 2,4-pyrimidinediamine compounds and their uses
granted -
US 8911743
Haemophilus parasuis polypeptides and methods of use
granted -
US 8911729
Stem cell factor inhibitor
granted -
US 8911733
Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions
granted -
US 8911728
High-affinity fully functional soluble single-domain human CD4, antibodies, and related fusion proteins
granted -
US 8912323
Multifunctional small molecules
granted -
US 8911722
Modulation of yeast-based immunotherapy products and responses
granted -
US 8911718
Methods for preparing polymeric reagents
granted
Frequently asked questions
How many pharma patents expire in 2034?
1,452 published patents in our USPTO index have expiration dates falling in calendar year 2034.